NASDAQ:DNLI Denali Therapeutics (DNLI) Stock Price, News & Analysis → The Department of Defense Has a New Drone Contractor (From The Tomorrow Investor) (Ad) Free DNLI Stock Alerts $16.85 -0.29 (-1.69%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$16.71▼$17.4250-Day Range$14.96▼$21.6952-Week Range$14.56▼$33.31Volume1.04 million shsAverage Volume1.16 million shsMarket Capitalization$2.40 billionP/E RatioN/ADividend YieldN/APrice Target$41.22 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Denali Therapeutics alerts: Email Address Denali Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside144.6% Upside$41.22 Price TargetShort InterestBearish8.33% of Float Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment0.45Based on 6 Articles This WeekInsider TradingSelling Shares$2.22 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.61) to ($2.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.69 out of 5 starsMedical Sector254th out of 903 stocksBiological Products, Except Diagnostic Industry32nd out of 153 stocks 3.5 Analyst's Opinion Consensus RatingDenali Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDenali Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Denali Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.33% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Denali Therapeutics has recently increased by 1.81%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDenali Therapeutics has received a 74.49% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for physiological diseases ", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Denali Therapeutics is -0.84. Previous Next 1.9 News and Social Media Coverage News SentimentDenali Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Denali Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for DNLI on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,218,802.00 in company stock.Percentage Held by InsidersOnly 7.90% of the stock of Denali Therapeutics is held by insiders.Percentage Held by Institutions92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Denali Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Denali Therapeutics are expected to decrease in the coming year, from ($2.61) to ($2.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Denali Therapeutics is -15.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Denali Therapeutics is -15.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Denali Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Denali Therapeutics Stock (NASDAQ:DNLI)Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Read More DNLI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DNLI Stock News HeadlinesApril 19, 2024 | insidertrades.comVicki L. Sato Sells 1,666 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) StockMay 7, 2024 | finance.yahoo.comDenali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic ShiftsMay 7, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.May 7, 2024 | finance.yahoo.comDenali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 7, 2024 | globenewswire.comDenali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 5, 2024 | americanbankingnews.comDenali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of "Buy" from AnalystsMay 2, 2024 | markets.businessinsider.comBuy Recommendation for DNLI: Promising Safety and Efficacy of Denali’s ALS Drug DNL343May 1, 2024 | globenewswire.comDenali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform TrialMay 7, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.April 29, 2024 | finance.yahoo.comIs There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?April 27, 2024 | americanbankingnews.comDenali Therapeutics (NASDAQ:DNLI) Sets New 12-Month Low at $14.56April 20, 2024 | nasdaq.comOversold Conditions For Denali Therapeutics (DNLI)April 17, 2024 | msn.comDenali Therapeutics (DNLI) Price Target Decreased by 5.45% to 42.01April 8, 2024 | tmcnet.comFlagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio SciencesMarch 22, 2024 | msn.comDenali Therapeutics files to sell 29.29M shares of common stock for holdersMarch 19, 2024 | finance.yahoo.comFurther weakness as Denali Therapeutics (NASDAQ:DNLI) drops 7.4% this week, taking three-year losses to 67%March 17, 2024 | finance.yahoo.comDNLI Apr 2024 12.500 putMarch 16, 2024 | finance.yahoo.comDNLI Apr 2024 10.000 callMarch 16, 2024 | finance.yahoo.comDNLI Apr 2024 17.500 putMarch 1, 2024 | markets.businessinsider.comStrong Growth and Value Potential Justify Buy Rating for Denali Therapeutics Despite DilutionFebruary 29, 2024 | markets.businessinsider.comGoldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To KnowFebruary 29, 2024 | markets.businessinsider.comBuy Rating Affirmed on Denali Therapeutics Amid Promising DNL310 Progress and ETV Technology PotentialFebruary 28, 2024 | markets.businessinsider.comStrong Buy Rating for Denali Therapeutics: Financial Stability and Promising Clinical AdvancementsFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Denali Therapeutics on Strong Pipeline and Extended Cash RunwayFebruary 28, 2024 | markets.businessinsider.com4 Analysts Assess Denali Therapeutics: What You Need To KnowFebruary 28, 2024 | marketwatch.comDenali Therapeutics Shares Rise 19% After $500M FinancingFebruary 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Denali Therapeutics (DNLI)See More Headlines Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/07/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:DNLI CUSIPN/A CIK1714899 Webwww.denalitherapeutics.com Phone(615) 866-8548FaxN/AEmployees445Year Founded2015Price Target and Rating Average Stock Price Target$41.22 High Stock Price Target$95.00 Low Stock Price Target$28.00 Potential Upside/Downside+143.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-145,220,000.00 Net Margins-36.51% Pretax Margin-43.93% Return on Equity-13.50% Return on Assets-11.38% Debt Debt-to-Equity RatioN/A Current Ratio13.65 Quick Ratio13.65 Sales & Book Value Annual Sales$330.53 million Price / Sales7.31 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book2.29Miscellaneous Outstanding Shares142,540,000Free Float131,279,000Market Cap$2.42 billion OptionableOptionable Beta1.39 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Ryan J. Watts Ph.D. (Age 48)Co-Founder, President, CEO & Director Comp: $1.15MDr. Alexander O. Schuth M.D. (Age 51)Co-Founder, CFO, COO & Secretary Comp: $802.29kDr. Marc Tessier-Lavigne Ph.D. (Age 64)Co-Founder & Independent Director Comp: $57.5kDr. Carole Ho M.D. (Age 51)Chief Medical Officer & Head of Development Comp: $802.29kMr. Tyler M. Nielsen (Age 46)Senior Vice President of Corporate Finance Dr. Dana AndersenChief Technical and Manufacturing OfficerMr. Joe Lewcock Ph.D.Chief Scientific OfficerDr. Laura HansenVice President of Investor RelationsMr. Chris WalshGeneral CounselMr. Mark RowenVice President of Corporate DevelopmentMore ExecutivesKey CompetitorsVericelNASDAQ:VCELApogee TherapeuticsNASDAQ:APGEKymera TherapeuticsNASDAQ:KYMRSana BiotechnologyNASDAQ:SANAGinkgo BioworksNYSE:DNAView All CompetitorsInsiders & InstitutionsSwiss National BankBought 1,500 shares on 5/7/2024Ownership: 0.153%Susquehanna Fundamental Investments LLCBought 211,017 shares on 5/7/2024Ownership: 0.148%AIA Group LtdSold 7,044 shares on 5/7/2024Ownership: 0.043%ClariVest Asset Management LLCBought 7,568 shares on 5/7/2024Ownership: 0.033%SG Americas Securities LLCBought 7,141 shares on 5/7/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions DNLI Stock Analysis - Frequently Asked Questions Should I buy or sell Denali Therapeutics stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DNLI shares. View DNLI analyst ratings or view top-rated stocks. What is Denali Therapeutics' stock price target for 2024? 8 Wall Street analysts have issued 1-year price targets for Denali Therapeutics' shares. Their DNLI share price targets range from $28.00 to $95.00. On average, they expect the company's share price to reach $41.22 in the next twelve months. This suggests a possible upside of 144.6% from the stock's current price. View analysts price targets for DNLI or view top-rated stocks among Wall Street analysts. How have DNLI shares performed in 2024? Denali Therapeutics' stock was trading at $21.46 at the start of the year. Since then, DNLI stock has decreased by 21.5% and is now trading at $16.85. View the best growth stocks for 2024 here. Are investors shorting Denali Therapeutics? Denali Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 9,410,000 shares, an increase of 12.3% from the March 15th total of 8,380,000 shares. Based on an average daily volume of 1,180,000 shares, the days-to-cover ratio is presently 8.0 days. Approximately 8.4% of the shares of the company are sold short. View Denali Therapeutics' Short Interest. When is Denali Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our DNLI earnings forecast. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) announced its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by $0.05. Denali Therapeutics had a negative trailing twelve-month return on equity of 13.50% and a negative net margin of 36.51%. During the same quarter in the prior year, the business earned ($0.75) earnings per share. What ETFs hold Denali Therapeutics' stock? ETFs with the largest weight of Denali Therapeutics (NASDAQ:DNLI) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO).BNY Mellon Innovators ETF (BKIV). What is Ryan Watts' approval rating as Denali Therapeutics' CEO? 1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG). When did Denali Therapeutics IPO? Denali Therapeutics (DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager. Who are Denali Therapeutics' major shareholders? Denali Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (9.85%), Principal Financial Group Inc. (0.79%), Wasatch Advisors LP (0.29%), Swiss National Bank (0.15%), Susquehanna Fundamental Investments LLC (0.15%) and BNP Paribas Financial Markets (0.05%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato. View institutional ownership trends. How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DNLI) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorElon Musk Secret Crypto Plot ExposedCrypto 101 MediaBiden replacement revealed?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsObama’s Forever Term [exposed]Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.